UNSPSC 51384902: Rimazolium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 967Y95129A, chemically known as 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-4h-pyrido(1,2-a)pyrimidinium but generally known as rimazolium, which bears US NIH Compound Identifier 71940. European Medicines Agency schedules Rimazolium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15142MIG.

World Health Organization schedules rimazolium in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, RIMAZOLIUM remains the US FDA Preferred Term for this commodity. Rimazolium bears US NLM identifiers UMLS ID C0072022 and NCI Concept Code C84138. SMILES: O=C1N2C(CCCC2[N](CC1C(=O)OCC)C)C.

UNSPSC 51384902 Rimazolium is a Commodity code under which state and local governments procure naloxone, pharmaceutical products, drug deactivation systems, and related medicines through competitive solicitations and cooperative purchasing agreements. The code encompasses both emergency-response medications and broader pharmacy benefit programs, with issuing bodies ranging from county health departments to state human services commissions and multistate cooperative purchasing alliances. Recent activity shows county health authorities and state departments managing health benefit procurement, with cooperative purchasing vehicles like MMCAP extending reach across multiple participating jurisdictions.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs for self-insured state employee health plans and pharmacy benefit optimization. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must maintain relationships with authorized wholesalers, comply with cGMP and FDA requirements, and meet substantial insurance minimums including $5 million commercial general liability coverage.